公开(公告)号：US20240352427A1

公开(公告)日：2024-10-24

申请号：US18747005

申请日：2024-06-18

Applicant: KANEKA CORPORATION

Inventor： Sho KAMBAYASHI ,  Yoshikazu KAWAI

IPC: C12N5/074

CPC classification number: C12N5/0696 ,  C12N2501/603 ,  C12N2501/727

Abstract: The purpose of the present invention is to produce a large amount of a high-quality pluripotent stem cell stock. A mass production method of a pluripotent stem cell stock that comprises thawing starting cells followed by adhesion culture to thereby stabilize the cell conditions, and then growing the cells to a cell count that enables suspension culture. Subsequently, the cells are suspension cultured while precisely controlling the culture environment to thereby grow a large number of high-quality cells. Then, a stock is prepared at a low temperature from the cells having been grown by the suspension culture.

公开(公告)号：US20250145965A1

公开(公告)日：2025-05-08

申请号：US18835550

申请日：2023-02-02

Applicant: RIKEN ,  KANEKA CORPORATION

Inventor： Yohei HAYASHI ,  Mami TAKASAKI ,  Sho KAMBAYASHI ,  Yoshikazu KAWAI

IPC: C12N5/074 ,  C12N15/86

Abstract: To provide a method for producing induced pluripotent stem cells (iPS cells) that can initialize somatic cells without using feeder cells or a substrate. For production of iPS cells, the following steps are carried out: I. introducing an initialization gene into a somatic cell; and II. performing initialization and amplification culture of the cell into which the gene has been introduced, in a liquid medium comprising at least one of a protein kinase Cβ (PKCβ) inhibitor and a WNT inhibitor under a suspension culture condition.

公开(公告)号：US20240247236A1

公开(公告)日：2024-07-25

申请号：US18437911

申请日：2024-02-09

Applicant: KANEKA CORPORATION ,  RIKEN

Inventor： Sho KAMBAYASHI ,  Yoshikazu KAWAI ,  Yohei HAYASHI ,  Mami TAKASAKI

IPC: C12N5/074 ,  C12N5/0735

CPC classification number: C12N5/0696 ,  C12N5/0606 ,  C12N2500/24 ,  C12N2500/38 ,  C12N2501/115 ,  C12N2501/15 ,  C12N2501/33 ,  C12N2501/415 ,  C12N2501/727

Abstract: The death of some pluripotent stem cells in suspension culture of pluripotent stem cells is avoided. When performing the suspension culture of the pluripotent stem cells, a liquid medium that does not substantially contain a PKCβ inhibitor is used for a single-cell state and a liquid medium containing a PKCβ inhibitor and a WNT inhibitor is used after a cell mass is formed.

公开(公告)号：US20240191185A1

公开(公告)日：2024-06-13

申请号：US18283744

申请日：2022-03-25

Applicant: KANEKA CORPORATION

Inventor： Sho KAMBAYASHI ,  Yoshikazu KAWAI

IPC: C12N5/0735 ,  C12N5/074

CPC classification number: C12N5/0606 ,  C12N5/0696 ,  C12N2500/02

Abstract: The pluripotent stem cell culture environment is appropriately controlled to improve production efficiency, and to suppress cell death when passaging pluripotent stem cells from suspension culture. Pluripotent stem cells subjected to suspension culture in a perfusion mode under appropriate medium perfusion conditions are passaged in the subsequent culture step, thereby improving passage efficiency. By strictly controlling the amount of medium perfused in line with the progress of culture of pluripotent stem cells and/or adjusting the amount of carbon dioxide gas supplied in line with the progress of culture of pluripotent stem cells, culture efficiency and productivity can be remarkably improved.

公开(公告)号：US20240035000A1

公开(公告)日：2024-02-01

申请号：US18265609

申请日：2021-12-07

Applicant: KANEKA CORPORATION ,  RIKEN

Inventor： Sho KAMBAYASHI ,  Yohei HAYASHI ,  Mami TAKASAKI

IPC: C12N5/074 ,  C12N5/0735

CPC classification number: C12N5/0696 ,  C12N5/0606 ,  C12N2501/727 ,  C12N2501/724 ,  C12N2501/115 ,  C12N2501/15

Abstract: This invention is intended to suppress cell death occurring at the time of transition of adherent culture of pluripotent stem cells to suspension culture thereof. Pluripotent stem cells are subjected to adherent culture in a liquid medium comprising a PKCβ inhibitor and a TNKS inhibitor and then to suspension culture.

公开(公告)号：US20240034998A1

公开(公告)日：2024-02-01

申请号：US18375035

申请日：2023-09-29

Applicant: KANEKA CORPORATION

Inventor： Terasu KAWASHIMA ,  Yoshikazu KAWAI ,  Sho KAMBAYASHI

IPC: C12N5/077

CPC classification number: C12N5/0657 ,  C12N2513/00 ,  C12N2521/00

Abstract: An object of the present invention is to easily obtain a large number of cardiomyocyte spheroids from cardiomyocytes separated into single cells. The present invention provides a method of producing a cardiomyocyte spheroid, the method comprising a step of culturing cardiomyocytes separated into single cells while stirring liquid in a container in which the cardiomyocytes are suspended, thereby causing aggregation of the cells.

公开(公告)号：US20230094568A1

公开(公告)日：2023-03-30

申请号：US17798947

申请日：2021-02-12

Applicant: KANEKA CORPORATION ,  RIKEN

Inventor： Kazuhiro TAKEUCHI ,  Masato IBUKI ,  Yohei HAYASHI ,  Mami TAKASAKI ,  Sho KAMBAYASHI ,  Yoshikazu KAWAI

IPC: C12N5/074

Abstract: Pluripotent stem cells are suspension-cultured with the undifferentiated state thereof maintained. In suspension culture of pluripotent stem cells, the undifferentiated state is maintained by the presence of a PKC inhibitor, especially, a PKCβ inhibitor, and a tankyrase inhibitor (TNKS inhibitor).